ANALYSIS: Inside The Sun-Novartis Japan Deal
This article was originally published in PharmAsia News
Like all pharma transactions, the Sun-Novartis deal in Japan took its time to come to fruition – around six months from conceptualization is a fair guesstimate.
You may also be interested in...
Kyowa, the Japanese arm of Indian major Lupin, is buying a basket of mature products including CNS drugs Rhythmy and Resmit from Shionogi. As innovator companies seek to shed older products in Japan, generic firms, especially Indian ones, are taking advantage to expand in the world's second largest pharmaceutical market.
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Novartis counters speculation around pandemic-related staff cutbacks in India, saying that it actually upped the number of hires across its operations since January 2020. A senior executive separately provides a buoyant outlook for the Swiss firm’s global services operations in Hyderabad, which has added a significant number of new roles.